Online first
Review article
Published online: 2024-07-31
Bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.
1
, 1
, 1
Abstract
Modern immunochemotherapy protocols allow 60–70% of diffuse large B-cell lymphoma (DLBCL) patients to be cured by first-line therapy. Those with primary resistance or early relapse have a poor prognosis, and classical salvage regimens are effective in less than 20% of these patients. Targeted chemotherapy and immunotherapy protocols are considered the current standard of care. Chimeric antigen receptor T cell (CAR-T cell) therapy and bispecific antibodies (BsAbs) are regarded as the two most effective methods. Epcoritamab and glofitamab are novel BsAbs approved for the treatment of DLBCL after two lines of systemic therapy. Their high efficacy and safety have been confirmed in phase II multicenter studies. BsAbs are an alternative to CAR-T cell therapy in patients who do not qualify for it or who cannot wait for CAR-T cell preparation due to rapidly progressing disease. Although BsAbs are approved as monotherapy, combinations with chemotherapy and immunomodulatory agents are being explored in ongoing clinical studies. The high efficacy of BsAbs has prompted further research into their potential role in earlier lines of treatment, including first line and debulking before CAR-T cell therapies.
Keywords: bispecific antibodiesdiffuse large B-cell lymphomaepcoritamabglofitamabrefractoryrelapsed
References
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16): 1800–1808.
- Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022; 386(4): 351–363.
- Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018; 29(8): 1822–1827.
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23): 1540–1545.
- Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987; 316(24): 1493–1498.
- Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998; 16(10): 3264–3269.
- Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003; 102(6): 1989–1996.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27): 4184–4190.
- Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016; 51(1): 51–57.
- Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(11): 1729–1736.
- Epperla N, Kumar A, Abutalib SA, et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transplant Cell Ther. 2023; 29(9): 548–555.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in tefractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–2544.
- Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254): 839–852.
- Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2): 155–165.
- Salles G, Duell J, González-Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7): 978–988.
- Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000; 18(16): 3025–3030.
- Caimi PF, Ai WZ, Alderuccio JP, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024; 109(4): 1184–1193.
- Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018; 24(19): 4785–4797.
- Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016; 127(11): 1410–1416.
- Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021; 398(10306): 1157–1169.
- Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol. 2021; 39(18): 1959–1970.
- Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5): e327–e339.
- Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5): 481–491.
- Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 387(24): 2220–2231.
- Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023; 41(12): 2238–2247.
- Ayyappan S, Kim W, Kim T, et al. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2023; 142(Supplement 1): 436–436.
- Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023; 13(1): 116.
- Sośnia O, Puła B. Update on management of diffuse large B-cell lymphoma Richter's transformation. Acta Haematol Pol. 2024; 55(2): 97–107.
- Kater A, Ye J, Sandoval-Sus J, et al. Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022; 140(Supplement 1): 850–851.
- Cheah C, Assouline S, Baker R, et al. Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter's transformation. Blood. 2023; 142(Supplement 1): 614–614.